Interferon-alpha in the Treatment of Essential Thrombocythemia

References

• Fialkow J. P., Faguet G. B., Jacobson R. J., Vaidya K., Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58: 916–919
   PubMed Web of Science ®Google Scholar
• Schafer A. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 69–96
   Google Scholar
• van Genderen P. J., Michiels J. J. Primary thrombocythemia: diagnosis, clinical manifestations and management. Ann. Hematol. 1993; 67: 57–62
   PubMed Web of Science ®Google Scholar
• Griesshammer M., Selfried E., Heimpel H. Essentielle Thrombozythämie. Klinische Bedeutung, Diagnostik und Therapie. Dtsch. Med. Wschr. 1993; 118: 1412–1417
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Jahn M., Baumann B., Köpcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 1988; 61: 2487–2496
   PubMed Web of Science ®Google Scholar
• Michiels J. J., Abels J., Stecketee J., van Vliet H. D., Vuzevsky V. D. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann. Intern. Med. 1985; 102: 466–471
   PubMed Web of Science ®Google Scholar
• van Genderen P. J., Michiels J. J. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythemia. Presse. Med. 1994; 23: 73–77
   PubMed Web of Science ®Google Scholar
• Belluci S., Janvier M., Tobelem G., Flandrin G., Charpak Y., Berger R., Bolton M. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986; 58: 2440–2447
   PubMed Web of Science ®Google Scholar
• Fenaux P., Simon M., Caulier M. T., Lai J. L., Goudemand J., Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549–556
   PubMed Web of Science ®Google Scholar
• Cortelazzo S., Viero P., Finazzi G., D'Emilio A., Rodeghiero F., Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol. 1990; 8: 556–562
   PubMed Web of Science ®Google Scholar
• Millard F. E., Hunter C. S., Anderson M., Edelman M. J., Kosty M. P., Luiken G. A., Martino G. G. Clinical manifestations of essential thrombocythemia in young adults. Am. J. Hematol. 1990; 33: 27–31
   PubMed Web of Science ®Google Scholar
• Mitus A. J., Barbui T., Shulman L. N., Rosenthal D. S., Viero P., Cortelazzo S., Schafer A. I. Hemostatic complications in young patients with essential thrombocythemia. Am. J. Med. 1990; 88: 371–375
   PubMed Web of Science ®Google Scholar
• Randi M. L., Fabris F., Girolami A. Thrombocytosis in young people: Evaluation of 57 cases diagnosed before the age of 40. Blut 1990; 60: 233–237
   PubMedGoogle Scholar
• Cortelazzo S., Finazzi G., Ruggeri M., Vestri O., Galli M., Rhodeghiero F., Barbui T. Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis. N. Engl. J. Med. 1995; 332: 1132–1136
   PubMed Web of Science ®Google Scholar
• Murphy S., Iiiand H., Rosenthal D., Laszlo J. Essential thrombocythemia: An interim report from the polycythemia vera study group. Semin. Hematol. 1986; 23: 177–182
   PubMed Web of Science ®Google Scholar
• Berk P. D., Goldberg J. D., Donovan P. B., Fruchtman S. M., Berlin N. I., Wasserman L. R. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Sem. Hematol. 1986; 23: 132–143
   PubMed Web of Science ®Google Scholar
• Giles F. J. Maintenance therapy in the myeloproliferative disorders: The current options. Brit. J. Haematol. 1991; 79(Suppl. 1)92–95
   PubMed Web of Science ®Google Scholar
• Kasparau H., Bernhard M., Krieger O., Lutz D. Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia. Eur. J. Haematol. 1992; 48: 33–36
   PubMed Web of Science ®Google Scholar
• Middelhoff G., Boil I. A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. Ann. Haematol. 1992; 64: 207–209
   PubMed Web of Science ®Google Scholar
• Sacchi S., Tabilio A., Leoni P., Riccardi A., Vecchi A., Messora C., Bensi L., Falzetti F., Rupoli S., Ucci G., Martelli F. Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term aIFN treatment. Ann. Hematol. 1993; 66: 245–246
   PubMed Web of Science ®Google Scholar
• Talpaz M., Mavligit G., Keating M., Walters R. S., Gutterman J. U. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann. Intern. Med. 1983; 99: 789–792
   PubMed Web of Science ®Google Scholar
• Ludwig H., Linkesch W., Gisslinger H., Fritz E., Sinzinger H., Radaskiewicz T., Chott A., Flehner R., Micksche M. Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol. Immunother. 1987; 25: 266–273
   PubMed Web of Science ®Google Scholar
• Gisslinger H., Linkesch W., Fritz E., Ludwig H., Chott A., Radaskiewicz T. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1989; 2: 634–637
   Google Scholar
• Tichelli A., Gratwohl A., Berger C., Lori A., Würsch A., Dieterle A., Thomssen C., Nissen C., Holdener E., Speck B. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a. Blut 1989; 58: 15–19
   PubMedGoogle Scholar
• Talpaz M., Kurzrock R., Kantarjian H., O'Brien S., Gutterman J. U. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis. Am. J. Med. 1989; 86: 554–558
   PubMed Web of Science ®Google Scholar
• Ganser A., Carlo-Stella C., Greher J., Völkers B., Hölzer D. Effect of interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 1987; 70: 1173–1179
   PubMed Web of Science ®Google Scholar
• Gugliotta L., Bagnara G. P., Catani L., Gaggiol L., Guarni A., Zauli G. In vivo and in vitro inhibitory effect of interferon on megakaryocyte colony growth in essential thrombocythemia. Brit. J. Haematol. 1989; 71: 177–181
   PubMed Web of Science ®Google Scholar
• Chott A., Gisslinger H., Thiele J., Fritz E., Linkesch W. Interferon-alpha-induced morphological changes of megakaryocytes: A histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Brit. J. Haematol. 1990; 74: 10–16
   PubMed Web of Science ®Google Scholar
• Wadenvik H., Kutti J., Ridell B., Revesz P., Jacobsson S., Magnusson B., Westin J., Vilen L. The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood 1991; 77: 2103–2108
   PubMed Web of Science ®Google Scholar
• Lazzarino M., Vitale A., Morra E., Gagliardi A., Bernasconi P., Torromeo C., Inverardi D., Burgio V., Castello A., Bernasconi C., Mandelli F. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. Brit. J. Haematol. 1989; 72: 173–177
   PubMed Web of Science ®Google Scholar
• Scheithauer W., Gisslinger H., Temsch E., Linkesch N., Linkesch W., Ludwig H. Effekt of recombinant interferon-a2c on reticuloendothelial function in patients with thrombocytosis. Journal of Interferon Research 1990; 10: 237–242
   PubMedGoogle Scholar
• Catani L., Gugliotta L., Cascione M. L., Mattioli Belmonte M., Vianelli N., Belardinelli A. R., Tufa S. Platelet function and interferon alpha-2a treatment in essential thrombocythemia. Eur. J. Haematol. 1991; 46: 158–162
   PubMed Web of Science ®Google Scholar
• Legrand C., Belluci S., Disdier M., Edelman L., Tobelem G. Platelet thrombospondin and glycoprotein VI abnormalities in patients with essential thrombocythemia: Effect of alpha-interferon treatment. Am. J. Hematol. 1991; 38: 307–313
   PubMed Web of Science ®Google Scholar
• Bellucci S., Harousseau L. J., Brice P., Tobelem G. Treatment Of essential thrombocytaemia by alpha 2a Interferon. Lancet 1988; 2((8617))960–961
   PubMed Web of Science ®Google Scholar
• Giles F. J., Gray A. G., Brozovic M., Grant I. R., Machin S. J., Richards J. D., Venutas S., Singer C. R., Yong K. L., Davies S. C., Hoffbrand A. V., Mehta A. B., Thomas M. J., Goldstone A. H. Alpha-interferon therapy for essential thrombocythemia. Lancet 1988; 1: 70–72
   Google Scholar
• Giralt M., Rubio D., Cortes M. T., San Miguel J., Steegmann J. L., Fernandes-Ranada J. M., Lopez-Borrasca A. Alpha interferon in the management of essential thrombocythemia. Eur. J. Cancer 1991; 27(Suppl 14)72–74
   Web of Science ®Google Scholar
• Gisslinger H., Chott A., Scheithauer W., Gilly B., Linkesch W., Ludwig H. Interferon in essential thrombocythemia. Brit. J. Haematol. 1991; 79(Suppl. 1)42–47
   PubMed Web of Science ®Google Scholar
• Sacchi S., Tabillo A., Leoni P., Riccardi A., Vecchi A., Messora C., Falzetti F., Rupoli S., Ucci G., Martelli M. F. Interferon alpha-2b in the long-term treatment of essential thrombocythemia. Ann. Hematol. 1991; 63: 206–209
   PubMed Web of Science ®Google Scholar
• Turri D., Mitra M. E., Di-Trapani R., Lipari M. G., Perricone R., Cajozzo A. Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica 1991; 76: 75–77
   PubMed Web of Science ®Google Scholar
• Yatanagas X., Meletis J., Plata E., Viniou N., Deligiannis F., Tsekoura C., Voscaridou E., Boussiotis V., Rombos J., Vayopoulos G., Kittas C., Fessas P. Alpha interferon treatment of essential thrombocythemia and other myeloproliferative disorders with excessive thrombocytosis. Eur. J. Cancer 1991; 27(Suppl 4)69–71
   Web of Science ®Google Scholar
• Seewann H. L. Interferontherapie bei essentiellen Thrombozythämien. Widen. Med. Wochenschr. 1993; 143: 420–424
   PubMedGoogle Scholar
• Rametta V., Ferrara F., Marottoli V., Matera C., Mettivier V., Cimino R. Recombinant interferon alpha-2b as treatment of essential thrombocythaemia. Acta. Haematol. 1994; 91: 126–129
   PubMed Web of Science ®Google Scholar
• Törnebohm-Roche E., Merup M., Lockner D., Paul C. Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. Am. J. Hematol. 1994; 48: 163–167
   Web of Science ®Google Scholar
• Catani L., Gugliotta L., Zauli G., Bagnara G. P., Antonelli G., Belmonte M. M., Visanelli N., Bonsi L., Brunelli M. A., Tura S. In vitro inhibition of interferon alpha-2a and antiproliferative activity by antibodies developed during treatment for essential thrombocythaemia. Hematologica 1992; 77: 318–321
   PubMedGoogle Scholar
• Hehlmann R., Heimpel H., Hasford J., Kolb H. J., Pralle H., Hossfeld D. K., Queisser W., Löffler H., Hochhaus A., Heinze B., Georgii A., Bartram C. R., Grieβhammer M., Bergmann L., Essers U., Falge C., Queisser U., Meyer P., Schmitz N., Eimermacher H., Walter F., Fet T W., Kleeberg U. E., Käbisch A., Nerl C., Zimmermann R., Meuret G., Tichelli A., Kanz L., Tigges F. J., Schmid L., Brockhaus W., Tobler A., Reiter A., Perker M., Emmerich B., Verpoort K., Zankovich R., Wussow P., Prümmer O., Thiele J., Buhr T., Ansari H. and the German CML Study Group. (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood, 84: 4064–4077
   PubMed Web of Science ®Google Scholar
• Anger B., Jansson J. W., Schrezenmeier H., Hehlmann R., Heimpel H., Bartram C. R. Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms. Leukemia 1990; 4: 258–261
   PubMed Web of Science ®Google Scholar
• El Kassar N., Hetel G., Briere J., Grandchamp B. Clonal analysis of hematopoietic cells in essential thrombocythemia. Brit. J. Haematol. 1995; 90: 131–137
   PubMed Web of Science ®Google Scholar
• Shibata K., Shimamoto Y., Suga K., Sano M., Matsuzaki M., Yamaguchi M. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation- a brief review of recent literature. Acta. Haematol. 1994; 91: 84–88
   PubMed Web of Science ®Google Scholar
• Fruchtman S. M., Kaplan M. E., Peterson P., Mack K., Berk P. D., Wasserman L. R., for the PVSG. Acute leukemia (AL), hydroxyurea (HU) and polycthemia vera (PV): An analysis of risk of the polycythemia vera study group (PVSG). Blood 1994; 84(suppl 1)2058
   Google Scholar
• Anagrelide study group. Anagrelide, a therapy for thrombocythemic states. Experience in 577 patients. Am. J. Med. 1992; 92: 69–76
   PubMed Web of Science ®Google Scholar
• Spencer C. M., Brogden R. N. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythemia. Drugs 1994; 47: 809–822
   PubMed Web of Science ®Google Scholar
• Mazur E., Rosmarin A. G., Sohl P. A., Newton J. L., Naredran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992; 79: 1931–1937
   PubMed Web of Science ®Google Scholar